Hybrid panel of biomarkers can be useful in the diagnosis of pleural and peritoneal effusions

Imagem de Miniatura
Arquivos
art_FARIA_Hybrid_panel_of_biomarkers_can_be_useful_in_2019.PDF (434.26 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
Citação
CLINICA CHIMICA ACTA, v.497, p.48-53, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: In clinical practice, pleural and peritoneal effusions are usual diagnosis. We evaluated the performance of a hybrid panel of biomarkers in the diagnosis of the main diseases affecting pleura and/or peritoneum. Methods: Samples of pleural/ peritoneal fluid from 120 patients were evaluated for: CEA (carcinoembryonic antigen), VEGF-A (vascular endothelial growth factor A), PD-L1/B7-H1 (programmed death-ligand 1), NGAL (neutrophil gelatinase-associated lipocalin), TREM-1 (triggering receptor expressed in myeloid cells type-1) and IFN gamma (gamma-interferon) by Luminex (R); CALP (Calprotectin) by ELISA, and ADA (adenosine deaminase) by enzymatic deamination. Results: For malignant effusion (ME) diagnosis, CEA and NGAL presented superior performance than VEGF-A, PD-L1 and CALP. A CEA-NGAL association showed good sensitivity (86.6%) and accuracy (79.2%). For non-tuberculous infectious effusion (NTBIE), NGAL presented the best performance with sensitivity (75.0%), specificity (62.0%) and accuracy (65.0%) higher than TREM-1 and CALP; however, when associated, although with good sensitivity, there was important decrease in specificity. For tuberculous pleural effusion (TPE), IFNy-ADA presented excellent sensitivity (100%), specificity (87.6%), NPV (100%) and accuracies (similar to 90%). Conclusions: CEA, NGAL, ADA and IFNy were useful in discriminating ME and TPE. However, for NTBIE diagnosis, the hybrid panel did not demonstrate advantages over the classic parameters.
Palavras-chave
Biomarkers, Pleural effusion, Ascites, Malignancy, Infection, Malignancy, Tuberculosis
URI
https://observatorio.fm.usp.br/handle/OPI/34100
Referências
  1. Angeleri A, 2016, GASTROENTEROL RES, V9, P17, DOI 10.14740/gr700w
  2. Antonangelo L, 2015, CURR ONCOL, V22, pE336, DOI 10.3747/co.22.2563
  3. Argyris PP, 2018, J DENT RES, V97, P674, DOI 10.1177/0022034518756330
  4. Barraud D, 2011, CRIT CARE CLIN, V27, P265, DOI 10.1016/j.ccc.2010.12.006
  5. Bauvois B, 2018, CANCERS, V10, DOI 10.3390/cancers10090336
  6. Bolignano D, 2008, AM J KIDNEY DIS, V52, P595, DOI 10.1053/j.ajkd.2008.01.020
  7. Candido S, 2014, ONCOTARGET, V5, P1576, DOI 10.18632/oncotarget.1738
  8. Chappell William H., 2018, Advances in Biological Regulation, V69, P43, DOI 10.1016/j.jbior.2018.05.002
  9. Chen M, 2017, POSTGRAD MED, V129, P644, DOI 10.1080/00325481.2017.1331112
  10. Fafliora E, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12978
  11. Froudarakis ME, 2008, RESPIRATION, V75, P4, DOI 10.1159/000112221
  12. Gumus A, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-49
  13. Jedynak M, 2018, ARCH IMMUNOL THER EX, V66, P299, DOI 10.1007/s00005-017-0499-x
  14. Kaleta EJ, 2013, CLIN BIOCHEM, V46, P814, DOI 10.1016/j.clinbiochem.2013.02.010
  15. Kanai T, 2003, J IMMUNOL, V171, P4156, DOI 10.4049/jimmunol.171.8.4156
  16. KLOCKARS M, 1991, CHEST, V99, P623, DOI 10.1378/chest.99.3.623
  17. Li YX, 2018, ACTA BIOCH BIOPH SIN, V50, P307, DOI 10.1093/abbs/gmx147
  18. Lippi G, 2013, CLIN CHIM ACTA, V418, P59, DOI 10.1016/j.cca.2012.12.020
  19. Molina R, 2012, TUMOR BIOL, V33, P463, DOI 10.1007/s13277-011-0275-1
  20. Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003
  21. Pelham CJ, 2014, EXPERT OPIN THER PAT, V24, P1383, DOI 10.1517/13543776.2014.977865
  22. Petruccioli E, 2013, J INFECTION, V66, P475, DOI 10.1016/j.jinf.2013.02.004
  23. Porcel J.M., 2003, MED SCI MONITOR, V5, P27
  24. Sales RKB, 2009, RESPIROLOGY, V14, P1128, DOI 10.1111/j.1440-1843.2009.01621.x
  25. Sanchez-Otero N, 2012, BRIT J CANCER, V107, P1876, DOI 10.1038/bjc.2012.478
  26. Sant GR, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0025-y
  27. SCHREIBER RD, 1992, INT J IMMUNOPHARMACO, V14, P413, DOI 10.1016/0192-0561(92)90171-G
  28. Wang XF, 2014, ASIAN PAC J CANCER P, V15, P363, DOI 10.7314/APJCP.2014.15.1.363
  29. Wu KA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04189-4
  30. Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - ODS/03